April 25, 2024 article from El País.
A London librarian has analyzed millions of articles in search of uncommon terms abused by artificial intelligence programs. He detected a sudden rise in the use of certain words, such as meticulously (up 137%), intricate (117%), commendable (83%) and meticulous (59%.)
“Andrew Gray estimates that at least 60,000 scientific studies (more than 1% of those analyzed in 2023) were written with the help of ChatGPT — a tool launched at the end of 2022 — or similar. ‘I think extreme cases of someone writing an entire study with ChatGPT are rare,’ says Gray, a 41-year-old Scottish librarian. In his opinion, in most cases artificial intelligence is used appropriately to ‘polish’ the text — identify typos or facilitate translation into English — but there is a large gray area, in which some scientists take the assistance of ChatGPT even further, without verifying the results. ‘Right now it is impossible to know how big this gray area is, because scientific journals do not require authors to declare the use of ChatGPT, there is very little transparency,’ he laments.”
Let's start with the truth!
Support the Broken Science Initiative.
Subscribe today →
recent posts
Metabolic health, medical education, and the case for bringing clinicians and coaches together
At the 2026 Unbreakable Health Retreat in Miami, Emily Kaplan hosted a panel with Bob Kaplan, Professor Thomas Seyfried, and Dr. Derek Lee on what it means to treat cancer as a metabolic disease. They discussed the glucose-ketone index (GKI), nutritional ketosis, and strategies aimed at restricting the fuels cancer cells depend on while considering how metabolic therapy can fit alongside standard cancer treatment.
The conversation also addressed the practical realities patients face when trying to pursue a metabolic approach within the conventional oncology system, including questions about nutrition, repurposed drugs, inherited cancer risk, and how to evaluate different treatment options. Seyfried and Lee connected these clinical questions back to mitochondrial dysfunction, fermentation, and the metabolic vulnerabilities that may offer additional targets for cancer treatment.
An abbreviated version of this discussion is available here, for free.
At the 2026 Unbreakable Health Retreat in Miami, Professor Thomas Seyfried presented the case that cancer is fundamentally a mitochondrial metabolic disease rather than primarily a genetic one. He contrasts the dominant somatic mutation theory with a metabolic model in which impaired mitochondrial respiration drives a shift toward fermentation, dysregulated cell growth, and the mutations commonly associated with cancer.
Citing the work of Otto Warburg and research from his lab at Boston College, Seyfried explains how cancer cells rely heavily on fermentable fuels—particularly glucose and glutamine—and why mitochondrial dysfunction sits upstream of many of the genetic abnormalities seen in tumors. He also discusses reactive oxygen species, altered cellular signaling, and the role of mitochondria in regulating cell growth and behavior.
The presentation then turns to the therapeutic implications of this model. Seyfried explains strategies aimed at placing tumor cells under metabolic stress by restricting the fuels they depend on, including ketogenic metabolic therapy and approaches targeting glucose and glutamine. For Seyfried, the therapeutic target follows directly from the biology: restrict the fuels cancer cells depend on, exploit their metabolic weaknesses, and treat mitochondrial dysfunction as the central feature of the disease.
An abbreviated version of this discussion is available here, for free.
MetFix and BSI Members can view the full 54-minute video.
